Most Read Articles
Roshini Claire Anthony, 29 May 2020

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

3 days ago
Use of metformin is effective in preventing hyperglycaemia in nondiabetic cancer patients exposed to high-dose prednisone-based chemotherapy, results of a randomized study have shown.
6 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.

Year-long belapectin has limited efficacy in NASH patients with cirrhosis, portal hypertension

18 Apr 2020

Consistent and long-term administration of belapectin is safe but has limited efficacy in patients with nonalcoholic steatohepatitis (NASH), cirrhosis and portal hypertension, a new study has found.

Researchers conducted a phase IIb randomized trial on 162 eligible patients. They received either 2 mg/kg (n=54) or 8 mg/kg (n=54) of belapectin infusions biweekly, or placebo (n=54). The trial lasted for 52 weeks and the primary endpoint was change in hepatic venous pressure gradient (HVPG) from baseline. Liver histology and other liver-related outcomes were set as secondary outcomes.

In all treatment groups, the large majority of participants reported at least one treatment-emergent adverse event, with rates ranging from 89 percent to 98.1 percent. Most of the events were grade 1 or 2 in severity. Infections and infestations were the most common adverse events.

Side effects related to the medication were reported in 24 percent of the placebo group, 36 percent of the 2-mg/kg belapectin group and 42.5 percent of the 8-mg/kg belapectin arm.

Despite the good safety profile, evidence of medication efficacy was sparse. At end of treatment, the least square mean changes in HVPG from baseline were not significantly different among the three treatment arms. A similarly null result was obtained when change values in both active treatment groups were compared to the placebo (p=1.0 for both).

However, researchers found that in patients without varices at baseline, the 2 mg/kg belapectin dose significantly decreased HVPG over time. This suggests the need for further evaluation in phase III studies.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 29 May 2020

For coffee drinkers, drinking filtered coffee may be tied to a lower mortality risk, including cardiovascular disease (CVD)-related mortality, a study from Norway suggested.

3 days ago
Use of metformin is effective in preventing hyperglycaemia in nondiabetic cancer patients exposed to high-dose prednisone-based chemotherapy, results of a randomized study have shown.
6 days ago
Use of corticosteroid is not associated with improved outcomes in idiopathic pulmonary fibrosis (IPF) patients admitted to the hospital with acute exacerbation (AE), reveals a recent study. In addition, corticosteroids may even contribute to reduced overall survival following exacerbation.
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.